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The pNNx Heart Rate Variability Statistics:   
An Application to Neuroautonomic Dysfunction   
of Clozapine-Treated Subjects 
 
 
 
ObjectiveaaThe percentage of successive normal cardiac interbeat intervals greater than 50 
msec (pNN50) is a widely used heart rate variability measure, which is useful in identify-
ing the neuroautonomic dysfunction of psychiatric disorders. However, pNN50 is only one 
member of a larger family of pNNx statistics, where x is greater than 0 msec. The potential 
application of the general pNNx statistics has not yet been explored in the psychiatric field. 
The authors examined the pNNx statistics in clozapine-treated subjects and normal controls 
to evaluate the usefulness of the general pNNx statistics. 
MethodsaaSixty-one schizophrenic patients treated with clozapine and fifty-nine normal 
controls were evaluated. Probability values for the differences between the groups at each 
pNN value (range: pNN1-pNN100) were calculated using data obtained from a 30-minute 
electrocardiogram. 
ResultsaaThe conventional pNN50 and pNNx values with x<50 msec were all signifi-
cantly lower in the patient group (p<0.05). The distinction between the two groups was more 
prominent at pNN values less than 50 msec than that observed at pNN50. The maximum 
separation between groups occurred at pNN5 (68.2±19.1 vs. 22.5±20.5, p<10
-22). 
ConclusionaaThe pNNx with x<50 msec provided more robust discrimination between the 
groups than the conventional pNN50, suggesting the importance of analyzing very small 
variations of interbeat interval in discriminating normal and pathological heart rate pat-
terns. The results also suggest that the general pNNx statistics may be applied and useful in 
evaluating the neuroautonomic dysfunction in patients treated with clozapine, complement-
ing the traditionally computed pNN50 value.   Psychiatry  Invest  2009;6:294-298
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Introduction 
 
The analysis of heart rate variability (HRV), i.e., the variation in the cardiac inter-
beat interval over time, has proven to be useful in evaluating the neurocardiac func-
tion in various neuropsychiatric disorders and in patients receiving psychotropic me-
dications.
1-5 It is a useful non-invasive method providing a dynamic window into the 
alterations of complex neuronal activity in the central and peripheral nervous sys-
tems, and has significant utility in broader clinical and research applications.
6 
Recently, it has been demonstrated that linear and novel non-linear measures of 
HRV are different in patients with antipsychotic treatment compared to normal control 
subjects, suggesting significant neuroautonomic abnormalities associated with anti-
psychotics.
7-11 
Among the various parameters of HRV, the pNN50 statistic, which is defined as the  
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percentage of successive normal interbeat intervals grea-
ter than 50 msec, is one of the most widely used meas-
ures.
12,13 Previous reports have suggested that pNN50 
was diminished in patients receiving antipsychotics such 
as clozapine or olanzapine.
14,15 Considering that pNN50 
reflects the vagal modulation, these results imply the neu-
roautonomic abnormality associated with decreased para-
sympathetic modulation in patients treated with these 
drugs.
8,10,14,15  
However, the pNN50 value is only one member of a 
larger family of pNNx statistics, where x is greater than 0 
msec.
16 Mietus et al.
16 reported that pNN thresholds as low 
as 20 msec or less were more useful and powerful than the 
standard 50 msec threshold in discriminating normal sub-
jects and pathological group such as heart disease, and 
suggested the utility of evaluating the general pNNx st-
atistics rather than selecting only one fixed measure.   
The applications of the general pNNx statistics and their 
usefulness have not yet been explored or rigorously test-
ed in patients with antipsychotic treatment in which the 
HRV has already proven to be both practical and useful 
in evaluating the autonomic functioning.
4,8,17-19  
In the present study, we comprehensively examined the 
pNNx statistics in normal controls and clozapine-treated 
patients to identify the optimum pNN values distingui-
shing the two groups and to evaluate the usefulness of the 
general pNNx statistics in patients treated with clozapine. 
 
Methods 
 
Subjects 
The study protocol was approved by the Institutional 
Review Board of the Seoul National University Hospital, 
and all procedures used in the study were conducted in 
accordance with international ethical standards, Declar-
ation of Helsinki. Sixty-one schizophrenic subjects (44 
men, 17 women) treated at the Seoul National University 
Hospital Schizophrenia Outpatient Clinic, and 59 normal 
control subjects (34 men, 25 women) were evaluated. In-
formed consent was obtained from all subjects after a full 
explanation of the study procedure. 
The patients were diagnosed according to the Diag-
nostic and Statistical Manual of Mental Disorders, 4th 
edition.
20 None of the patients had suffered either from 
any diseases known to affect the autonomic cardiac func-
tion, such as cardiovascular, neurological or endocrinolo-
gical diseases, or from drug dependence. The patients had 
a mean age of 34.0±7.8 years and a mean duration of 
illness of 10.0±5.1 years. Of 61 patients, 9 (14.8%) pa-
tients were married, and 52 (85.2%) were unmarried or 
divorced. The mean number of admissions in the past 
was 3.6±2.2. The mean Clinical Global Impression-Se-
verity
21 score was 2.9±0.6 and the mean current Global 
Assessment of Functioning
22 score was 54.9±14.5. The 
mean total Positive and Negative Syndrome Scale
23 score 
of the patients was 66.1±11.6 (range=41-88). 
All patients had been treated with stable doses of clo-
zapine as monotherapy for at least 4 weeks. The mean 
daily dose of clozapine was 257.6±109.1 mg. The normal 
control subjects were screened by a complete medical and 
psychiatric examination and none had a history of any 
disease or medication that might affect the autonomic 
nervous system. There were no significant differences be-
tween the patient and control groups with regard to age 
(mean years: 34.0±7.8 vs. 31.4±9.0, t=1.64, p=0.10) or 
gender distribution (male %: 72.1 vs. 57.6, χ2=2.77, p= 
0.10).  
 
Assessment of heart rate variability 
 
Data Acquisition and Preprocessing 
To exclude the influence of diurnal variations, the HRV 
measurements were begun between 10 : 00 a.m. and 11 : 00 
a.m.
24 All subjects were instructed to avoid coffee and 
nicotine for at least one hour prior to the assessment of 
their autonomic function. After each subject had been al-
lowed to adapt to the experimental conditions for about 
15 minutes, a 30-minute single channel (3-lead) electro-
cardiogram (ECG) recording was performed in the seated 
position at complete rest. The ECG signal was amplified 
using an OP-Amplifier (MAX232) and was digitized at 
a sampling rate of 400 Hz (width path 0.05-35 Hz). From 
the ECG of each subject, HRV was extracted by using 
previously proposed preprocessing procedures such as 
low-pass filtering, detrending, and R-peak detection of dif-
ferential ECG signals.
2,25 In the event of failure to extract 
HRV from the ECG due to noise, recordings were ex-
cluded. Recordings with non-sinus beats that were more 
than 1% of the total number of beats were also excluded. 
Premature beats and artifacts were carefully eliminated 
automatically and manually by visual inspection of all 
RR intervals. 
 
The pNNx Statistics 
The statistical time-domain measures of instantaneous 
heart rates are divided into two classes: 1) those derived 
from direct measurements of normal-to-normal intervals, 
and 2) those derived from the differences between suc-
cessive interbeat intervals. One of the approaches to the 
measurement of HRV is via the percentage of absolute 
differences in successive normal sinus intervals that are 
greater than some threshold value. The most commonly 
used threshold is 50 msec, and the statistic obtained is 
termed pNN50.
12 The conventional 50 msec used in the  
 
 
 
 
Neuroautonomic Dysfunction of Clozapine-Treated Subjects 
296 Psychiatry Invest 2009;6:294-298 
pNN50 measurements represents an arbitrary threshold, 
and is only one member of a general pNNx family of st-
atistics. In the present study, the general pNNx statistics 
were obtained by estimating the percentage of succes-
sive RR interval differences whose absolute value ex-
ceeds x msec.
16 
 
Statistical analysis 
Probability values for the differences between the gr-
oups at each pNN value were calculated using two-tailed 
t-tests as previously proposed.
16 The interclass correl-
ations between the HRV measures were assessed using 
Pearson’s two-tailed correlation test. A critical value of 
p<0.01 was used in statistical evaluation. Statistical analyses 
were performed using Statistical Package for the Social 
Sciences (SPSS) version 17.0 (SPSS, Chicago, IL, USA). 
 
Results 
 
A comparison of the pNNx measures between the gr-
oups is shown in Figure 1 and Table 1. The mean data 
length was not significantly different between the pa-
tient and control groups (1912.9±422.9 vs. 1868.0±365.6, 
t=0.66, p=0.51). The conventional pNN50 value and 
other pNNx parameters such as pNN10, pNN20, pNN30, 
and pNN40 were all significantly lower in the patient 
group than in the control group (p<0.05). However, as 
shown in Figure 1, the distinction between the two groups 
was more prominent at pNN values less than 50 msec in 
comparison with that observed at the conventional pNN50 
value. The maximum separation between groups occurr-
ed at pNN5 (68.2±19.1 vs. 22.5±20.5, p<10
-22). In order 
to check the reliability of pNNx, the interclass correla-
tions between the square root of the mean squared differ-
ences of successive normal sinus intervals (RMSSD), the 
high frequency (HF) power and pNNx were examined. 
In the patient group, the pNNx values with x≤20 msec 
were shown to correlate significantly well with RMSSD 
(r=0.99 with pNN10) and with HF (r=0.96 with pNN20). 
In contrast to the patient group, the pNNx values with 
x≥30 msec showed most significant correlations with 
RMSSD (r=0.97 with pNN30) and with HF (r=0.94 with 
pNN50) in the control group. 
 
Discussion 
 
In the present study, the pNNx statistics beyond the 
standard pNN50 were comprehensively examined to ev-
aluate their usefulness in discriminating normal subjects 
and clozapine-treated patients. We found that pNNx with 
x<50 msec provides more robust discrimination between 
the groups than the conventional pNN50 value. To the best 
TABLE 1. Comparison of the pNNx measures between clozapine-treated schizophrenic patients and normal control subjects 
pNNx measures  Patient group (N=61) Control  group  (N=59) t  value  p  value 
pNN50 (%) 0.13  (00.55)  05.36 (08.99)  0-4.47 <10-4 
pNN40 (%) 0.38  (01.48)  08.87 (12.76)  0-5.08 <10-5 
pNN30 (%) 1.05  (03.45) 14.78  (17.17)  0-6.03 <10-7 
pNN20 (%) 2.93  (07.55) 25.88  (21.68)  0-7.69 <10-10 
pNN10 (%) 9.48  (15.08) 48.90  (22.91) -11.10  <10-18 
Values are presented as mean (standard deviation). pNNx: the percentage of absolute differences in successive normal cardiac 
interbeat intervals greater than x msec   
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FIGURE 1. A: The percentage of successive normal cardiac interbeat intervals greater than each given interval (pNNx) versus the NN
interval in normal control (n=59) and clozapine-treated schizophrenia (n=61) groups. B: The differences between the mean pNNx values of
normal control subjects and those of schizophrenic patients and the corresponding p values. The most significant separation between the
two groups is around x=5 msec.  
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of our knowledge, this is the first report to investigate the 
general pNNx HRV statistics in patients treated with psy-
chotropic medication. The results of our study suggest that 
the pNNx statistics may be useful in evaluating the neuro-
autonomic dysfunction in patients treated with clozapine, 
complementing the traditionally computed pNN50 value. 
The most significant separation between the two groups 
was observed at pNN5, indicating the importance of an-
alyzing very small variations of interbeat interval in dis-
criminating normal and pathological heart rate behavior 
patterns.
16 Previous studies have shown that pNN50, which 
is a good index of parasympathetic cardiac modulation, was 
significantly diminished in schizophrenic patients.
10,14,15 
The conventional time domain HRV measures, such as 
RMSSD including pNN50 were estimated from the dif-
ferences between successive interbeat intervals. Both RM-
SSD and pNN50 were reported to be useful in reflecting 
the fast alteration of parasympathetic activity and also 
evaluating the effects of various antipsychotics on auto-
nomic neurocardiac function (ANF).
10,15,24,26 Previous st-
udies have shown that the HF fluctuation of RR inter-
vals mainly reflects the vagal modulation, and that HF, 
which is related to respiratory sinus arrhythmia (RSA), 
is another index to assess the fast parasympathetic mo-
dulation.
18,27,28 In the present study, the pNNx values with 
x≤20 msec were shown to correlate significantly well 
with RMSSD and with HF in the patient group, while the 
pNNx values with x≥30 msec showed most significant 
correlations with RMSSD and with HF in the control 
group. The difference of significant interclass correla-
tions between the two groups supports previous reports 
that the pNN50 index were not sufficiently sensitive to 
detect the effects of certain antipsychotic or anticholi-
nergic medication on ANF.
29 According to our study, the 
pNNx values with x≤20 msec instead of the conventio-
nal 50 msec might be useful candidates for the detection 
of subtle changes of parasympathetic and vagal activity 
in patients receiving various kinds of antipsychotic drugs. 
In addition, the parameters can be useful in HRV bio-
feedback measures to assess RSA activity.
27,28,30 
It should be noted that clozapine has potent anticho-
linergic and parasympatholytic effects.
24 Evidence now 
exists for a strong association between reduced HRV and 
psychotropic drugs with anticholinergic properties include-
ing antipsychotics and tricyclic antidepressants.
4,8-10,24,31 
In addition, the effects of alpha adrenoceptor modulat-
ion on HRV via sympathetic and parasympathetic inputs 
were reported.
19,32,33 Therefore, a significant reduction 
in pNNx statistics is assumed to be explicitly as-so-
ciated with the direct effects of clozapine, although the 
psychotic symptom itself, might contribute to the decre-
ased heart rate dynamics. Since the novel atypical anti-
psychotics not only affect the dopaminergic receptors, 
but also exert significant effects on the serotonergic, cho-
linergic, and α-adrenergic receptors, neurocardiac funct-
ion integrity can be differentially affected by the distinct 
effects of these drugs on various receptors in the central 
and peripheral nervous systems.
24 Further studies are war-
ranted to examine the differential effects of the various 
atypical drugs on the general pNNx statistics.   
The interpretation of the results of the present study 
should be considered in light of some limitations. Since 
the clozapine plasma level was not measured, we could 
not exclude the possibility that the plasma drug concen-
tration might have influenced the pNNx values. Consi-
dering that the relationship between plasma antipsycho-
tic drug level and heart rate dynamics may change de-
pending on the phase of drug treatment,
9 future studies 
should include measurement of plasma drug concentr-
ation. It is possible that the decreased heart rate dynamics 
observed in clozapine-treated subjects are associated with 
the psychotic symptom itself, as well as with the effects 
of the medication.
10,34-36 Recent studies revealed cardiac 
autonomic dysfunction in patients with acute schizoph-
renia, which appears to be mainly related to reduced va-
gal and increased sympathetic modulation.
10,34-36 The cross-
sectional design of the study limits the firm interpreta-
tion of the results observed. Future prospective studies are 
required to evaluate the heart rate behavior in drug-naïve 
schizophrenic patients and to investigate the contribution 
of antipsychotic treatment to neuroautonomic modulation 
in these patients.
37  
In conclusion, the present study shows that pNNx with 
x<50 msec provides more robust discrimination between 
the groups than the conventional pNN50 value, suggesting 
the importance of analyzing very small variations of in-
terbeat interval in discriminating normal and pathologi-
cal heart rate behavior patterns. The results imply that the 
general pNNx statistics may be applied and useful in 
evaluating the neuroautonomic dysfunction in patients 
treated with clozapine, complementing the traditionally 
computed pNN50 value. Subtle fluctuations in sinus rhy-
thm quantified by pNNx statistics are thought to provide 
information about the very short term control of heart 
rate dynamics related to parasympathetic regulation.
12,13,16 
Novel analysis of HRV basing on the threshold of suc-
cessive RR interval differences may serve as a useful non-
invasive method providing a window into the alterations 
of complex interrelationships between brain and heart, 
and may have significant utility in clinical and research 
applications.
6 
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